Monte Rosa Therapeutics, Inc. reported $29M of revenue over the trailing twelve months, −84% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $29M (to Q2 2026). Net income: −$161M, trailing twelve months to Q2 2026. Free cash flow: −$32M, trailing twelve months to Q2 2026. Operating margin: −946%, trailing twelve months to Q2 2026.

GLUEMonte Rosa Therapeutics, Inc.

Healthcare

$10.32+63% 1Y

$10.32

$6.3352 weeks$25.31

GLUE as reported

Monte Rosa Therapeutics, Inc. reported $29M of revenue over the trailing twelve months, −84% on the year before. 8 reported series are charted on this page, each one as filed.

$29M

Revenue, trailing twelve months · to Q2 2026 · −84% against the twelve months before

Net income: −$161M
Net income · −767% year on year · trailing twelve months to Q2 2026
Free cash flow: −$32M
Free cash flow · −234% year on year · trailing twelve months to Q2 2026
Operating margin: −946%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for GLUE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$29M	−84%	Q2 2026
Net income	−$161M	−767%	Q2 2026
EPS	−$1.76	−589%	Q2 2026
Operating margin	−946%	n/a	Q2 2026
Net margin	−853%	n/a	Q2 2026
ROE	−17%	n/a	Q2 2026
ROA	−11%	n/a	Q2 2026
Free cash flow	−$32M	−234%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.